Rhamnus frangula L. (Frangula alnus Miller)
The herbal monograph selects and summarises scientific studies and textbooks regarding efficacy, dosage and safety to support the therapeutic uses of frangula bark.
This herbal drug by definition consists of the dried, whole or fragmented bark of the stems and branches of Rhamnus frangula L. (Frangula alnus Miller).
Studies with its main characteristic constituents frangula-emodin derivatives such as glucofrangulins A and B and frangulins A, B and C are included.
The therapeutic indication is short term treatment of occasional constipation.
Administration of frangula bark addresses posology; its duration of use; contra-indications; special warnings; special precautions for use; interactions with other medicinal products; other forms of interaction; in pregnancy and lactation; its effects on ability to drive; undesirable effects; overdose.
In vitro experiments with various constituents of frangula bark demonstrate platelet inhibiting and antiproliferative effects.
In vivo experiments with frangula bark or its extracts in animals demonstrate laxative properties.
Controlled clinical studies with frangula bark demonstrated its use as a laxative in human patients with habitual constipation.
Pharmacokinetics of orally administered anthranoid glycosides of frangula bark, such as frangulins and glucofrangulins are assumed to act like sennosides in the intestine of animals and humans.
Preclinical safety data were assessed in toxicity studies.
Safety data were assessed in epidemiological studies.
The selection of literature cited in the monograph is aimed at bringing together relevant information about the possible physiological roles of frangula bark and its major constituents.
- Rhamnus frangula L. (Frangula alnus Miller)
- Frangulae cortex
- Frangula bark
- Constipation, occasional short term treatment